Harris Paul R, Calderón-Guerrero Otto Gerardo, Vera-Chamorro José Fernando, Lucero Yalda, Vásquez Margarita, Kazuo Ogata Silvio, Angulo Diana, Madrazo Armando, Gonzáles José, Rivero Anelsy, Gana Juan Cristóbal
Departamento de Gastroenterología y Nutrición Pediátrica, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Universidad del Valle, Cali, Colombia.
Rev Chil Pediatr. 2020 Oct;91(5):809-827. doi: 10.32641/rchped.vi91i5.2579.
The latest joint H. pylori NASPGHAN and ESPGHAN clinical guidelines published in 2016, contain 20 statements that have been questioned in practice regarding their applicability in Latin America (LA); in particular in relation to gastric cancer prevention.
We conduc ted a critical analysis of the literature, with special emphasis on LA data and established the level of evidence and level of recommendation of the most controversial claims in the Joint Guidelines. Two rounds of voting were conducted according to the Delphi consensus technique and a Likert scale (from 0 to 4) was used to establish the "degree of agreement" among a panel of SLAGHNP ex perts.
There are few studies regarding diagnosis, treatment effectiveness and susceptibility to antibiotics of H. pylori in pediatric patients of LA. Based on these studies, extrapolations from adult studies, and the clinical experience of the participating expert panel, the following recom mendations are made. We recommend taking biopsies for rapid urease and histology testing (and samples for culture or molecular techniques, when available) during upper endoscopy only if in case of confirmed H. pylori infection, eradication treatment will be indicated. We recommend that selected regional centers conduct antimicrobial sensitivity/resistance studies for H. pylori and thus act as reference centers for all LA. In case of failure to eradicate H. pylori with first-line treatment, we recommend empirical treatment with quadruple therapy with proton pump inhibitor, amoxi cillin, metronidazole, and bismuth for 14 days. In case of eradication failure with the second line scheme, it is recommended to indicate an individualized treatment considering the age of the pa tient, the previously indicated scheme and the antibiotic sensitivity of the strain, which implies performing a new endoscopy with sample extraction for culture and antibiogram or molecular resistance study. In symptomatic children referred to endoscopy who have a history of first or se cond degree family members with gastric cancer, it is recommended to consider the search for H. pylori by direct technique during endoscopy (and eradicate it when detected).
The evidence supports most of the general concepts of the NASPGHAN/ESPGHAN 2016 Guidelines, but it is necessary to adapt them to the reality of LA, with emphasis on the development of regional centers for the study of antibiotic sensitivity and to improve the correct selection of the eradication treatment. In symptomatic children with a family history of first or second degree gastric cancer, the search for and eradication of H. pylori should be considered.
2016年发布的幽门螺杆菌(H. pylori)最新版美国儿科学会胃肠病、肝病和营养学会(NASPGHAN)与欧洲儿科胃肠病、肝病和营养学会(ESPGHAN)联合临床指南包含20条声明,在实践中其在拉丁美洲(LA)的适用性受到质疑;特别是在胃癌预防方面。
我们对文献进行了批判性分析,特别强调拉丁美洲的数据,并确定了联合指南中最具争议主张的证据水平和推荐等级。根据德尔菲共识技术进行了两轮投票,并使用李克特量表(从0到4)来确定拉丁美洲胃肠病、肝病和营养学会(SLAGHNP)专家小组之间的“同意程度”。
关于拉丁美洲儿科患者幽门螺杆菌的诊断、治疗效果和抗生素敏感性的研究很少。基于这些研究、成人研究的推断以及参与专家小组的临床经验,提出以下建议。我们建议仅在确诊幽门螺杆菌感染且需要进行根除治疗时,在上消化道内镜检查期间取活检进行快速尿素酶和组织学检测(以及在可行时取样本进行培养或分子技术检测)。我们建议选定的区域中心开展幽门螺杆菌抗菌敏感性/耐药性研究,从而成为整个拉丁美洲的参考中心。如果一线治疗未能根除幽门螺杆菌,我们建议采用质子泵抑制剂、阿莫西林、甲硝唑和铋剂的四联疗法进行14天的经验性治疗。如果二线方案根除失败,建议根据患者年龄、先前使用的方案以及菌株的抗生素敏感性进行个体化治疗,这意味着要重新进行内镜检查并取样本进行培养和药敏试验或分子耐药性研究。对于有胃癌一级或二级家族史且接受内镜检查的有症状儿童,建议在内镜检查期间通过直接技术检测幽门螺杆菌(检测到后予以根除)。
证据支持NASPGHAN/ESPGHAN 2016年指南的大多数总体概念,但有必要使其适应拉丁美洲的实际情况,重点是发展抗生素敏感性研究的区域中心,并改善根除治疗的正确选择。对于有胃癌一级或二级家族史的有症状儿童,应考虑检测和根除幽门螺杆菌。